

IL-8 increases integrin expression and cell motility in human chondrosarcoma cells

Chun-Yi Lee¹, Chun-Yin Huang^{1,2}, Meng-Yi Chen², Ching-Yuang Lin¹,
Horng-Chaung Hsu^{1,3} and Chih-Hsin Tang^{4,5*}

¹Graduate Institute of Clinical Medical Science, China Medical University, Taichung,
Taiwan

²Department of Orthopaedic Surgery, China Medical University Beigang Hospital,
Yun-Lin County, Taiwan

³Department of Orthopaedic Surgery, China Medical University Hospital, Taichung,
Taiwan

⁴Department of Pharmacology, School of Medicine, China Medical University and
Hospital, Taichung Taiwan

⁵Graduate Institute of Basic Medical Science, China Medical University and Hospital,
Taichung, Taiwan

***: Author for Correspondence:**

Chih-Hsin, Tang, PhD.

Department of Pharmacology, School of Medicine, China Medical University

No. 91, Hsueh-Shih Road, Taichung, Taiwan

Tel: (886) 4-22052121 Ext. 7726. Fax: (886) 4-22333641.

E-mail: chtang@mail.cmu.edu.tw

Abstract

Chondrosarcoma is a type of highly malignant tumor with a potent capacity to invade locally and cause distant metastasis. Chondrosarcoma shows a predilection for metastasis to the lungs. Interleukin-8 (IL-8), a chemokine with a defining CXC amino acid motif, is known to possess tumorigenic and proangiogenic properties. Overexpression of IL-8 has been detected in many human tumors. However, the effects of IL-8 in migration and integrin expression in chondrosarcoma cells are largely unknown. In this study, we found that IL-8 increased the migration and the expression of $\alpha\beta3$ integrin in human chondrosarcoma cells. Activations of phosphatidylinositol 3-kinase (PI3K), Akt and AP-1 pathways after IL-8 treatment were demonstrated, and IL-8-induced expression of integrin and migration activity was inhibited by the specific inhibitor and mutant of PI3K, Akt and AP-1 cascades. Taken together, our results indicated that IL-8 enhances the migration of chondrosarcoma cells by increasing $\alpha\beta3$ integrin expression through the PI3K/Akt/AP-1 signal transduction pathway.

Running title: IL-8 induces the migration of chondrosarcoma

Key words: IL-8; Migration; Chondrosarcoma; Integrin; AP-1

Introduction

Chondrosarcoma is a malignant primary bone tumor with a poor response to currently-used chemotherapy or radiation treatment, making the management of chondrosarcomas a complicated challenge [Terek et al., 1998]. Clinically, surgical resection remains the primary mode of therapy for chondrosarcoma. Due to the absence of an effective adjuvant therapy, this mesenchymal malignancy has a poor prognosis and, therefore, it is important to explore a novel and adequate remedy [Yuan et al., 2005].

Interleukin-8 (IL-8), a member of the neutrophil-specific CXC subfamily of chemokines with ELR (Glu-Leu-Arg) motif, can act not only on leukocyte chemotaxis and inflammatory responses and infectious diseases but also on endothelial cells via their receptors to promote migration, invasion, proliferation and *in vivo* angiogenesis [Lee et al., 2005; Raman et al., 2007; Xie, 2001]. The biological action of IL-8 is mediated through binding to its receptors, CXCR1 (IL-8RA) and CXCR2 (IL-8RB), which are members of the seven transmembrane G-protein-coupled receptor family [Heidemann et al., 2003; Rollins, 1997]. It has been suggested that tumor cells produce IL-8 as an autocrine growth factor, which promote tumor growth, tissue invasion and metastatic spread [Xie, 2001]. Previous studies have revealed that highly metastatic solid tumors such as prostate, breast, melanoma and ovarian cancer constitutively express IL-8 [Huang et al., 2002; Xu and Fidler, 2000]. Moreover, IL-8 expression correlates with tumor cell growth and vascularity in gastric carcinoma [Kido et al., 2001]. However, the exact role of IL-8 in the progressive growth of chondrosarcoma remains unclear.

Decades of scrutiny into the molecular bases of cancer have largely focused on what causes oncogenic transformation and the incipient emergence of tumors [Gupta and Massague, 2006]. The invasion of tumor cells is a complex, multistage process. To facilitate cell motility, invading cells need to change the cell-cell adhesion properties, rearrange the extracellular matrix (ECM) environment, suppress anoikis and reorganize their cytoskeletons [Woodhouse et al., 1997]. Integrins are a family of

transmembrane adhesion receptors comprising 19 α and 8 β subunits that interact noncovalently to form up to 24 different heterodimeric receptors. The combination of different integrin subunits on the cell surface allows cells to recognize and respond to a variety of different ECM proteins including fibronectin, laminin, collagen and vitronectin [Humphries, 2000]. Because integrins are the primary receptors for cellular adhesion to ECM molecules, they act as crucial transducers of bidirectional cell signaling, regulating cell survival, differentiation, proliferation, migration and tissue remodeling [Stupack, 2007]. Activation and elevated expression of integrin-coupled signaling effectors have been implicated in the induction of a wide variety of human cancers, including those of the breast, colon, prostate, and ovaries [White et al., 2004]. In addition, integrin has also been implicated in metastasis of lung, breast, bladder and colon cancers [Heyder et al., 2005; Seales et al., 2005; Takenaka et al., 2000].

Previous studies have shown that IL-8 modulates cell migration and invasion in human cancer cells [Kido et al., 2001; Xie, 2001]. However, the effect of IL-8 on integrin expression and migration activity in human chondrosarcoma cells is mostly unknown. In this study, we explored whether IL-8 increased the migration and integrin expression of in human chondrosarcoma cells. In addition, phosphatidylinositol 3-kinase (PI3K), Akt and AP-1 signaling pathways may be involved in the increase of integrin expression and cell migration by IL-8.

Materials and Methods

Materials

Protein A/G beads, anti-mouse and anti-rabbit IgG-conjugated horseradish peroxidase, rabbit polyclonal antibodies specific for p-p85, p85, p-Akt, Akt, p-c-Jun, c-Jun, β -actin, c-Jun siRNA, control siRNA, control shRNA plasmid and IL-8 shRNA plasmid were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal antibody specific for α v β 3 integrin was purchased from Chemicon

(Temecula, CA). Ly294002, wortmannin, Akt inhibitor, curcumin and tanshinone IIA were purchased from Calbiochem (San Diego, CA, USA). The recombinant human IL-8, CXCR1 and CXCR2 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN, USA). The p85 (Δ p85; deletion of 35 amino acids from residues 479 to 513 of p85) and Akt (Akt K179A) dominant-negative mutants were gifts from Dr. W.M. Fu (National Taiwan University, Taipei, Taiwan). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Cell culture

The human chondrosarcoma cell line (JJ012) was kindly provided by the laboratory of Dr. Sean P. Scully (University of Miami School of Medicine, Miami, FL, USA). The human chondrosarcoma cell line (SW1353) was obtained from the American Type Culture Collection. The cells were cultured in Dulbecco's modified Eagle's medium/ α -minimum essential medium supplemented with 10% fetal bovine serum and maintained at 37°C in a humidified atmosphere of 5% CO₂.

Migration and invasion assay

The migration assay was performed using Transwell (Costar, NY, USA; pore size, 8- μ m) in 24-well dishes. For invasion assay, filters were precoated with 25 μ l Matrigel basement membrane matrix (BD Biosciences, Bedford, MA) for 30 min. The following procedures were the same for both migration and invasion assays. Cells were pretreated for 30 min with different concentrations of inhibitors, including the Ly294002, wortmannin, Akt inhibitor, curcumin, tanshinone IIA or vehicle control (0.1% DMSO). Approximately 1×10^4 cells in 200 μ l of serum-free medium were placed in the upper chamber, and 300 μ l of the same medium containing IL-8 was placed in the lower chamber. The plates were incubated for 24 h at 37°C in 5% CO₂, then cells were fixed in methanol for 15 min and stained with 0.05% crystal violet in PBS for 15 min. Cells on the upper side of the filters were removed with cotton-tipped swabs, and the filters were washed with PBS. Cells on the underside of the filters

were examined and counted under a microscope. Each clone was plated in triplicate in each experiment, and each experiment was repeated at least three times. The number of invading cells in each experiment was adjusted by the cell viability assay to correct for proliferation effects of IL-8 treatment (corrected invading cell number = counted invading cell number/percentage of viable cells) [Fong et al., 2008; Lu et al., 2010].

Wound-healing migration assay

For the wound-healing migration assay, cells were seeded on 12-well plates at a density of 1×10^5 cells/well in culture medium. At 24 h after seeding, the confluent monolayer of culture was scratched with a fine pipette tip, and migration was visualized by microscope and magnification. The rate of wound closure was observed at the indicated time.

Flow cytometric analysis

Human chondrosarcoma cells were plated in six-well dishes. The cells were then washed with PBS and detached with trypsin at 37°C. Cells were fixed for 10 min in PBS containing 1% paraformaldehyde. After being rinsed in PBS, the cells were incubated with mouse anti-human antibody against integrin (1:100) for 1 hr at 4°C. Cells were then washed again and incubated with fluorescein isothiocyanate-conjugated goat anti-rabbit secondary IgG (1:100; Leinco Tec. Inc., St. Louis, MO, USA) for 45 min and analyzed by flow cytometry using FACS Calibur and CellQuest software (BD Biosciences).

Western blot analysis

The cellular lysates were prepared as described previously [Tang et al., 2008]. Proteins were resolved on SDS-PAGE and transferred to Immobilon polyvinylidene difluoride (PVDF) membranes. The blots were blocked with 4% BSA for 1 hr at room temperature and then probed with rabbit anti-human antibodies against p-p85, p85, p-Akt, Akt or p-c-Jun (1:1000) for 1 hr at room temperature. After three

washes, the blots were subsequently incubated with a donkey anti-rabbit peroxidase-conjugated secondary antibody (1:1000) for 1 hr at room temperature. The blots were visualized by enhanced chemiluminescence using Kodak X-OMAT LS film (Eastman Kodak, Rochester, NY, USA).

Quantitative real-time PCR

Total RNA was extracted from chondrosarcomas using a TRIzol kit (MDBio Inc., Taipei, Taiwan). Two μg of total RNA was reverse transcribed into cDNA using oligo(dT) primer. The quantitative real-time PCR (qPCR) analysis was carried out using Taqman® one-step PCR Master Mix (Applied Biosystems, CA). One hundred ng of total cDNA were added per 25- μl reaction with sequence-specific primers and Taqman® probes. Sequences for all target gene primers and probes were purchased commercially (GAPDH was used as internal control) (Applied Biosystems, CA). qPCR assays were carried out in triplicate on a StepOnePlus sequence detection system. The cycling conditions were 10-min polymerase activation at 95 °C followed by 40 cycles at 95 °C for 15 s and 60 °C for 60 s. The threshold was set above the non-template control background and within the linear phase of target gene amplification to calculate the cycle number at which the transcript was detected (denoted C_T).

Establishment of stably transfected cells

IL-8 shRNA or control shRNA plasmids are transfected into cancer cells with Lipofetamine 2000 transfection reagent. Twenty-four hours after transfection, stable transfectants are selected in puromycin (Life Technologies) at a concentration of 10 $\mu\text{g}/\text{mL}$. Thereafter, the selection medium is replaced every 3 days. After 2 weeks of selection in puromycin, clones of resistant cells are isolated.

Statistics

The values given are means \pm S.E.M. The significance of differences between

the experimental groups and controls was assessed by Student's t test. *p* values <0.05 were considered significant.

Results

IL-8 directed migration of chondrosarcoma cells

IL-8 has been suggested to stimulate directional migration and invasion of human cancer cells [Kido et al., 2001; Xie, 2001]. IL-8-triggered migration in chondrosarcoma cells was examined using the Transwell assay with correction of IL-8-induced proliferation effects on human chondrosarcoma cells [Fong et al., 2008]. IL-8 directed human chondrosarcoma cell (JJ012 and SW1353 cells) migration (Fig. 1A). It was also found that the invasive ability of chondrosarcoma cells through the Matrigel basement membrane matrix was increased by IL-8 stimulation (Fig. 1B). On the other hand, IL-8 also increased wound healing activity in human chondrosarcoma cells (Fig. 1C). Interaction of IL-8 with its specific receptor CXCR1 and CXCR2 on the surface of cancer cells has been reported to induce cancer invasion [Heidemann et al., 2003; Rollins, 1997]. Pretreatment of cells for 30 min with anti-CXCR1 and CXCR2 antibody (5 µg/ml) markedly inhibited the IL-8-induced cell migration (Fig. 1D). These data suggest that IL-8-induced cancer migration may occur via CXCR1 and CXCR2 receptor.

Involvement of $\alpha v \beta 3$ integrin in the IL-8-directed migration of chondrosarcoma

Previous studies have shown significant expression of $\alpha v \beta 3$ integrin in human chondrosarcoma cells [Chen et al., 2009; Lai et al., 2009]. We therefore, hypothesized that $\alpha v \beta 3$ integrin may be involved in IL-8-directed chondrosarcoma cell migration. Flow cytometry analysis showed that IL-8 induced the cell surface expression of $\alpha v \beta 3$ integrin dose-dependently (Fig. 2A). To confirm this finding, expression of mRNA for the integrins in response to IL-8 was analyzed by qPCR. Treatment of JJ012 cells with IL-8 induced the mRNA expression of αv and $\beta 3$ integrin (Fig. 2B).

Pretreatment of cells for 30 min with anti- $\alpha\beta3$ monoclonal antibody (mAb) (10 $\mu\text{g/ml}$) markedly inhibited the IL-8-induced cell migration (Fig. 2C). The cyclic RGD peptide (cyclo-RGDfV) has been reported to bind $\alpha\beta3$ at high affinity and block its function effectively at low concentrations [Brooks et al., 1996]. Treatment of cells with cyclic RGD, but not cyclic RAD, inhibited the IL-8-induced migration of chondrosarcoma (Fig. 2C). In addition, CXCR1 and CXCR2 mAb also reduced IL-8-enhanced integrin expression (Fig. 2D). These data suggest that IL-8/CXCR-induced cancer migration may occur via up-regulation of $\alpha\beta3$ integrin receptor.

PI3K and Akt signaling pathways are involved in the $\alpha\beta3$ -induced integrin up-regulation and migration of human chondrosarcoma cells

PI3K/Akt signaling pathway can be activated by a variety of growth factors, such as insulin and nerve growth factors [Horowitz et al., 2004]. Treatment of cells with IL-8 led to a significant increase of phosphorylation of p85 subunit of PI3K (Fig. 3A). To explore whether PI3K is involved in IL-8-induced cells migration, PI3K inhibitor Ly294002 and wortmannin were used. As shown in Fig 3B&C, pretreatment of cells with Ly294002 or wortmannin inhibited IL-8-induced migration activity and integrin expression of chondrosarcoma. Transfection of cells with p85 mutant also antagonized the potentiating effect of IL-8 (Fig. 3B&C). We then directly measured the Akt phosphorylation in response to IL-8 stimulation. Figure 4A shows that IL-8 increased Akt phosphorylation in a time-dependent manner. Furthermore, Akt inhibitor or mutant also antagonized IL-8-induced cell migration and integrin expression (Fig. 4B&C). Taken together, these results indicate that the PI3K and Akt pathway are involved in IL-8-induced migration and $\alpha\beta3$ integrin expression of human chondrosarcoma cells.

AP-1 signaling pathway is involved in IL-8-induced integrin up-regulation and migration activity

As mentioned above, AP-1 activation is necessary for the migration and invasion of human chondrosarcoma cells [Hou et al., 2009; Tan et al., 2009]. To examine whether AP-1 activation is involved in IL-8-induced cancer migration, an AP-1 inhibitor, curcumin and tanshionone IIA were used. Fig. 5A shows that chondrosarcoma cells pretreated with curcumin and tanshionone IIA inhibited IL-8-induced chondrosarcoma cell migration. In addition, treatment of cells with curcumin or tanshionone IIA also antagonized IL-8-induced expression of $\alpha\text{v}\beta\text{3}$ integrin (Fig. 5B). AP-1 activation was further evaluated by analyzing the accumulation of phosphorylated c-Jun in the nucleus. Treatment of cells with IL-8 resulted in a marked accumulation of phosphorylated c-Jun in the nucleus (Fig. 5C). Transfection of cells with c-Jun siRNA suppressed the expression of c-Jun (data not shown). IL-8-induced cell migration and integrin expression was also inhibited by c-Jun siRNA but not by control siRNA (Fig. 5D). Taken together, these data suggest that activation of the CXCR1/CXCR2, PI3K, Akt, c-Jun, and AP-1 pathways are required for the IL-8-induced increase of cell migration and integrin expression in human chondrosarcoma cells.

Decreased cell motility in IL-8-shRNA over-expression clone

To further confirm IL-8-mediated cell migration and $\alpha\text{v}\beta\text{3}$ integrin expression in human chondrosarcoma cells, IL-8-shRNA expression cells were established. The IL-8 expression level in stable transfectants was compared using Western blotting. The expression of IL-8 was dramatically inhibited by IL-8-shRNA orientation in JJ012/IL-8-shRNA cells (Fig. 6B). We next characterized the cellular growth rate of control cells and transfectants by performing the MTT assay 1-6 days after cell seeding. No appreciable difference in cell growth ability was evident in these cells (data not shown), suggesting that IL-8 does not have any mitogenic effect in human chondrosarcoma cells. Furthermore, the migratory ability of these transfectants was analyzed using a Transwell migration assay. Knockdown of IL-8 expression inhibited the migratory ability by approximately 73% in JJ012 cells (Fig. 6A). In addition,

knockdown IL-8 also reduced αv and $\beta 3$ integrin expression in JJ012 cells (Fig. 6B). Therefore, human chondrosarcoma cells with a higher tendency to migrate expressed more IL-8 and $\alpha v\beta 3$ integrin.

Discussion

IL-8 activates target genes involved in differentiation, survival, apoptosis and proliferation. It also manipulates the process of tumorigenesis and tumor progression [Raman et al., 2007; Xie, 2001]. However, the effect of IL-8 on migration activity in chondrosarcoma is mostly unknown. Using migration, invasion and wound healing analysis, we found that IL-8 increased cell motility in human chondrosarcoma cells. Moreover, over-expression of IL-8 shRNA inhibited the migratory ability by approximately 73% in JJ012 cells. Our data provided the evidence that the expression of IL-8 is associated with a metastatic phenotype of chondrosarcoma cells. IL-8 exerts its effects through interaction with specific IL-8 receptors [Heidemann et al., 2003; Rollins, 1997]. We found that the CXCR1 and CXCR2 Ab reduced IL-8-mediated migration and integrin expression. Therefore, our data suggest a critical role for CXCR1 and CXCR2 receptor in the IL-8-mediated cell migration and integrin expression in human chondrosarcoma cells.

Integrins link the ECM to intracellular cytoskeletal structures and signaling molecules and are implicated in the regulation of a number of cellular processes, including adhesion, signaling, motility, survival, gene expression, growth, and differentiation [Shattil et al.]. Here we found that IL-8 increased $\alpha v\beta 3$ integrin expression by using flow cytometry analysis, which plays an important role during tumor metastasis [Beer and Schwaiger, 2008]. Furthermore, IL-8 also increased the mRNA levels of αv and $\beta 3$ integrins. **In the present study, we used $\alpha v\beta 3$ integrin antagonist (cyclic RGD) to determine the role of $\alpha v\beta 3$ integrin and found that it inhibited IL-8-induced cancer migration, indicating the possible involvement of $\alpha v\beta 3$ integrin in IL-8-induced migration in chondrosarcoma cells.** This was further

confirmed by the result that the $\alpha v\beta 3$ integrin antibody inhibited the enhancement of migration activity by IL-8, indicating the involvement of $\alpha v\beta 3$ integrin in IL-8-mediated induction of cancer migration.

A variety of growth factors stimulate cancer metastasis via signal-transduction pathways that converge to activate AP-1 complex of transcription factors [Ozanne et al., 2007]. The PI3K/Akt pathway is a major cascade mediating activation of the AP-1 signaling pathway in human cancer cells [Ozanne et al., 2007]. Phosphorylation of the p85 subunit is required for activation of the p110 catalytic subunit of PI3K [Qureshi et al., 2007]. We found IL-8-enhanced the p85 subunit phosphorylation in human chondrosarcoma cells. Pre-treatment of cells with PI3K inhibitors Ly294002 or wortmannin antagonized an increase in migration and integrin expression by IL-8 stimulation. This was further confirmed by the result that the dominant-negative mutant of p85 inhibited the enhancement of migration by IL-8. Moreover, we also found that IL-8 activated Akt Ser473 phosphorylation, while Akt inhibitor and Akt mutant inhibited IL-8-mediated cell migration and integrin expression. Our data indicates that PI3K/Akt could play an important role in the expression of integrin and migration of human chondrosarcoma cells. **We also examined the interaction of PI3K with CXCR or integrin after IL-8 stimulation. Treatment of cells with IL-8 increased p85 associated with CXCR1 and CXCR2 but not αv and $\beta 3$ integrin (Supplementary Figure S1A&B). Therefore, PI3K is associated with CXCR receptor but not integrin after IL-8 stimulation. Transfection of cells with IL-8 siRNA and p85 mutant but not Akt mutant and c-Jun siRNA reduced p85 associated with CXCR1 and CXCR2 (Supplementary Figure S1C&D). Therefore, Akt and c-Jun are downstream molecules of PI3K.**

Unlike other mesenchymal malignancies, such as osteosarcoma and Ewing's sarcoma, which have seen dramatic increases in long-term survival with the advent of systemic chemotherapy, chondrosarcoma continues to have a poor prognosis due to absence of an effective adjuvant therapy [Fong et al., 2007]. The metastatic potential for conventional chondrosarcomas correlates well with the histologic grade of the

tumor. But due to the relatively indolent growth rates of many low- and moderate-grade chondrosarcomas, ~15% of patients who die from metastatic disease do so >5 years after initial diagnosis [Fong et al., 2007]. Therefore, it is important to develop effective adjuvant therapy for preventing chondrosarcoma metastasis. We hypothesized that IL-8 would help to direct the metastasis of chondrosarcoma cells. We found that IL-8 increased the migration of chondrosarcoma cells. One of the mechanisms underlying IL-8-directed migration was up-regulation of $\alpha\text{v}\beta\text{3}$ integrin and activation of CXCR1/2, PI3K, Akt and AP-1 pathways (Fig. 6C). **Furthermore, the discovery of IL-8-mediated signaling pathway helps us understand the mechanism of human chondrosarcoma metastasis. IL-8 inhibitor or gene therapy may lead us to effective therapy in the future.**

Acknowledgments

This study was supported by grants from the National Science Council of Taiwan (NSC99-2628-B-002-025-MY3; NSC99-2628-B-002-014-MY3); China Medical University (CMU99-ASIA-10). We thank Dr. W.M. Fu for providing p85 and Akt mutants.

Figure legends

Fig. 1 IL-8-directed migration of human chondrosarcoma cells

(A&B) JJ012 or SW1353 cells were incubated with IL-8 for 24 hr, and *in vitro* migration and invasion was measured by Transwell after 24 hr. (C) Cells were treated with IL-8 for 48 hr, the wound-scratching assay was performed. (D) Cells were pretreated with CXCR1 or CXCR2 Ab (5 $\mu\text{g/ml}$) for 30 min followed by stimulation with IL-8 for 24 h, and *in vitro* migration was measured with the Transwell after 24 hr. Results are expressed as the mean \pm S.E. *, $p < 0.05$ compared with control.

Fig. 2 IL-8-directed migration activity of human chondrosarcoma cells involves up-regulation of $\alpha\text{v}\beta\text{3}$ integrin.

(A) Cells were incubated with IL-8, and the cell surface expression of $\alpha\text{v}\beta\text{3}$ integrin was determined using flow cytometry. (B) JJ012 cells were incubated with IL-8, and mRNA expression of αv and β3 integrin was determined using qPCR. (C) Cells were pretreated with $\alpha\text{v}\beta\text{3}$ monoclonal antibody (10 $\mu\text{g/ml}$), cyclic RGD (100 nM) or cyclic RAD (100 nM) for 30 min followed by stimulation with IL-8. The *in vitro* migration activity was measured after 24 hr. (D) Cells were pretreated with CXCR1 or CXCR2 Ab (5 $\mu\text{g/ml}$) for 30 min followed by stimulation with IL-8 for 24 h, and cell surface $\alpha\text{v}\beta\text{3}$ integrin was measured using flow cytometry. Results are expressed as the mean \pm S.E. *, $p < 0.05$ compared with control; #, $p < 0.05$ compared with IL-8-treated group.

Fig. 3 PI3K is involved in IL-8-induced migration and integrin up-regulation in human chondrosarcoma cells.

(A) Cells were incubated with IL-8 for indicated time intervals, and p-p85 was examined by western blot analysis. (B&C) Cells were pretreated for 30 min with Ly294002 (10 μM) and wortmannin (1 μM) or transfected with

dominant negative (DN) mutant of p85 for 24 hr followed by stimulation with IL-8, and *in vitro* migration and cell surface $\alpha\text{v}\beta\text{3}$ integrin was measured by Transwell and flow cytometry. Results are expressed as the mean \pm S.E. *, $p < 0.05$ compared with control; #, $p < 0.05$ compared with IL-8-treated group.

Fig. 4 Akt is involved in IL-8-induced migration and integrin up-regulation in human chondrosarcoma cells.

(A) Cells were incubated with IL-8 for indicated time intervals, and Akt phosphorylation was examined by western blot analysis. (B) Cells were pretreated for 30 min with Akt inhibitor (10 μM) or transfected with dominant negative (DN) mutant of Akt for 24 hr followed by stimulation with IL-8, and *in vitro* migration and cell surface $\alpha\text{v}\beta\text{3}$ integrin was measured by Transwell and flow cytometry. Results are expressed as the mean \pm S.E. *, $p < 0.05$ compared with control; #, $p < 0.05$ compared with IL-8-treated group.

Fig. 5 IL-8 induces cells migration and integrin up-regulation through AP-1.

(A&B) Cells were pretreated for 30 min with curcumin (10 μM) or tanshinone IIA (10 μM) followed by stimulation with IL-8, and *in vitro* migration and cell surface $\alpha\text{v}\beta\text{3}$ integrin was measured by Transwell and flow cytometry. (C) JJ012 cells were incubated with IL-8 for indicated time intervals, and c-Jun phosphorylation in nucleus was determined by western blot. (D) Cells were transfected with c-Jun or control siRNA for 24 h followed by stimulation with IL-8, and *in vitro* migration and cell surface $\alpha\text{v}\beta\text{3}$ integrin was measured by Transwell and flow cytometry. Results are expressed as the mean \pm S.E. *, $p < 0.05$ compared with control; #, $p < 0.05$ compared with IL-8-treated group.

Fig. 6 Knockdown of IL-8 inhibited the migratory ability in chondrosarcoma cells. (A) The *in vitro* migration activity of JJ012, JJ012/control-shRNA and JJ012/IL-8-shRNA cells was measured with the Transwell. (B) The protein levels of IL-8, αv and $\beta 3$ integrin in JJ012/control-shRNA and JJ012/IL-8-shRNA cells was examined by western blot analysis. Results are expressed as the mean \pm S.E. Schematic presentation of the signaling pathways involved in IL-8-induced migration and $\alpha v\beta 3$ integrin expression of chondrosarcoma. IL-8 and CXCR receptor interaction activates PI3K and Akt pathways, which in turn induces AP-1 activation, which leads to $\alpha v\beta 3$ integrin expression and increases the migration of human chondrosarcoma.

References

- Beer AJ, Schwaiger M. 2008. Imaging of integrin alphavbeta3 expression. *Cancer Metastasis Rev* 27:631-44.
- Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresch DA. 1996. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. *Cell* 85:683-93.
- Chen YJ, Wei YY, Chen HT, Fong YC, Hsu CJ, Tsai CH, Hsu HC, Liu SH, Tang CH. 2009. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. *J Cell Physiol* 221:98-108.
- Fong YC, Li TM, Wu CM, Hsu SF, Kao ST, Chen RJ, Lin CC, Liu SC, Wu CL, Tang CH. 2008. BMP-2 increases migration of human chondrosarcoma cells via PI3K/Akt pathway. *J Cell Physiol* 217:846-55.
- Fong YC, Yang WH, Hsu SF, Hsu HC, Tseng KF, Hsu CJ, Lee CY, Scully SP. 2007. 2-methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. *J Orthop Res* 25:1106-14.
- Gupta GP, Massague J. 2006. Cancer metastasis: building a framework. *Cell* 127:679-95.
- Heidemann J, Ogawa H, Dwinell MB, Rafiee P, Maaser C, Gockel HR, Otterson MF, Ota DM, Lugerling N, Domschke W, Binion DG. 2003. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. *J Biol Chem* 278:8508-15.
- Heyder C, Gloria-Maercker E, Hatzmann W, Niggemann B, Zanker KS, Dittmar T. 2005. Role of the beta1-integrin subunit in the adhesion, extravasation and migration of T24 human bladder carcinoma cells. *Clin Exp Metastasis* 22:99-106.
- Horowitz JC, Lee DY, Waghray M, Keshamouni VG, Thomas PE, Zhang H, Cui Z, Thannickal VJ. 2004. Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. *J Biol Chem* 279:1359-67.
- Hou CH, Hsiao YC, Fong YC, Tang CH. 2009. Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13. *Bone* 44:233-42.
- Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, Gudas JM, Bar-Eli M. 2002. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. *Am J Pathol* 161:125-34.

Humphries MJ. 2000. Integrin structure. *Biochem Soc Trans* 28:311-39.

Kido S, Kitadai Y, Hattori N, Haruma K, Kido T, Ohta M, Tanaka S, Yoshihara M, Sumii K, Ohmoto Y, Chayama K. 2001. Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas? *Eur J Cancer* 37:1482-7.

Lai TH, Fong YC, Fu WM, Yang RS, Tang CH. 2009. Stromal cell-derived factor-1 increase alphavbeta3 integrin expression and invasion in human chondrosarcoma cells. *J Cell Physiol* 218:334-42.

Lee CC, Cheng YW, Kang JJ. 2005. Motorcycle exhaust particles induce IL-8 production through NF-kappaB activation in human airway epithelial cells. *Journal of toxicology and environmental health. Part A* 68:1537-55.

Lu DY, Leung YM, Huang SM, Wong KL. 2010. Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. *Journal of cellular biochemistry* 110:141-50.

Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. 2007. Transcription factors control invasion: AP-1 the first among equals. *Oncogene* 26:1-10.

Qureshi HY, Ahmad R, Sylvester J, Zafarullah M. 2007. Requirement of phosphatidylinositol 3-kinase/Akt signaling pathway for regulation of tissue inhibitor of metalloproteinases-3 gene expression by TGF-beta in human chondrocytes. *Cell Signal* 19:1643-51.

Raman D, Baugher PJ, Thu YM, Richmond A. 2007. Role of chemokines in tumor growth. *Cancer Lett* 256:137-65.

Rollins BJ. 1997. Chemokines. *Blood* 90:909-28.

Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. 2005. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. *Cancer Res* 65:4645-52.

Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. *Nat Rev Mol Cell Biol* 11:288-300.

Stupack DG. 2007. The biology of integrins. *Oncology (Williston Park)* 21:6-12.

Takenaka K, Shibuya M, Takeda Y, Hibino S, Gemma A, Ono Y, Kudoh S. 2000. Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line. *Int J Oncol* 17:1187-94.

Tan TW, Yang WH, Lin YT, Hsu SF, Li TM, Kao ST, Chen WC, Fong YC, Tang CH. 2009. Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells. *Carcinogenesis* 30:258-68.

Tang CH, Chuang JY, Fong YC, Maa MC, Way TD, Hung CH. 2008. Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and

promotes osteoclastogenesis in human oral cancer cells. *Carcinogenesis* 29:1483-92.

Terek RM, Schwartz GK, Devaney K, Glantz L, Mak S, Healey JH, Albino AP. 1998. Chemotherapy and P-glycoprotein expression in chondrosarcoma. *J Orthop Res* 16:585-90.

White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, Muller WJ. 2004. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. *Cancer Cell* 6:159-70.

Woodhouse EC, Chuaqui RF, Liotta LA. 1997. General mechanisms of metastasis. *Cancer* 80:1529-37.

Xie K. 2001. Interleukin-8 and human cancer biology. *Cytokine Growth Factor Rev* 12:375-91.

Xu L, Fidler IJ. 2000. Interleukin 8: an autocrine growth factor for human ovarian cancer. *Oncol Res* 12:97-106.

Yuan J, Dutton CM, Scully SP. 2005. RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. *J Orthop Res* 23:1467-74.